While CM398 is a putative S2R antagonist [6], another putative S2R antagonist CT1812, though less selective between S2R and S1R, has been reported to be neuroprotective in mice and is in human clinical trials for Alzheimer’s disease [35]. Here, TMBIM4 is linked to early-onset autosomal dominant Alzheimer disease.